Sprout Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for Addyi (flibanserin 100 mg), a once-daily, non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Addyi is the first and only FDA-approved treatment for this condition, the most common form of female sexual dysfunction, affecting up to 1 in 10 women in the U.S. “It has been a remarkable journey to get to this breakthrough ...